Association of tirzepatide versus Glucagon-Like Peptide-1 receptor agonists with oral and periodontal outcomes in patients with type 2 Diabetes: A Global propensity Score-Matched cohort study.

Researchers compared dental and gum health outcomes in type 2 diabetes patients treated with tirzepatide versus GLP-1 receptor agonists over one year. Tirzepatide was associated with lower risks of periodontitis, tooth extraction, peri-implant complications, and oral infections compared with GLP-1 receptor agonists.

A plain-English summary of the study's own findings — we don't add our own claims or interpretation. Read the full paper for the complete methods and results, and apply your own clinical judgement.